

Michael Trauner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3005934/publications.pdf>

Version: 2024-02-01

579
papers

42,624
citations

1980

101
h-index

3714

179
g-index

668
all docs

668
docs citations

668
times ranked

37838
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
2	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	2.4	12
3	IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. <i>Hepatology</i> , 2023, 77, 20-32.	3.6	10
4	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	2.4	25
5	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	6.1	28
6	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	1.8	7
7	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
8	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	2.4	39
9	Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like) Tj ETQq1 1 0.784314 rgBT /Over 2022, 75, 125-139.	3.6	25
10	Alan Hofmann (1931-2021): A career well spent understanding bile acids. <i>Hepatology</i> , 2022, 75, 238-239.	3.6	0
11	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
12	Novel therapeutic targets for cholestatic and fatty liver disease. <i>Gut</i> , 2022, 71, 194-209.	6.1	84
13	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
14	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	3.6	18
15	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
16	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.4	11
17	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	1.8	64
18	Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1206-1218.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	1.8	26
20	Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance. <i>Hepatology</i> , 2022, 75, 1095-1109.	3.6	15
21	KIAA1363 affects retinyl ester turnover in cultured murine and human hepatic stellate cells. <i>Journal of Lipid Research</i> , 2022, 63, 100173.	2.0	4
22	Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. <i>Journal of Hepatology</i> , 2022, 77, 71-83.	1.8	31
23	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. <i>Journal of Personalized Medicine</i> , 2022, 12, 239.	1.1	7
24	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	1.8	59
25	Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 432-450.	8.2	119
26	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. <i>Advances in Medical Sciences</i> , 2022, 67, 154-162.	0.9	4
27	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	1.1	5
28	The "Viennese epidemic" of acute HCV in the era of direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2022, 29, 385-394.	1.0	10
29	Angiotensin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. <i>Digestive and Liver Disease</i> , 2022, 54, 1222-1229.	0.4	2
30	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	2.3	11
31	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. <i>Liver International</i> , 2022, 42, 1297-1307.	1.9	15
32	Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide" results of a real world study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 144-154.	1.9	46
33	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. <i>Journal of Hepatology</i> , 2022, 77, 1005-1013.	1.8	8
34	Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. <i>Journal of Clinical Medicine</i> , 2022, 11, 2863.	1.0	0
35	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	3.6	45
36	Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 918-930.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022, 4, 100513.	2.6	19
38	EASL Clinical Practice Guidelines on sclerosing cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 761-806.	1.8	84
39	Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2 ^{-/-} mouse model of sclerosing cholangitis via immunomodulatory effects. <i>Hepatology Communications</i> , 2022, 6, 2368-2378.	2.0	7
40	Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. <i>Journal of Hepatology</i> , 2022, 77, 1373-1385.	1.8	60
41	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	2.0	6
42	Current treatment of nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 190-204.	2.7	56
43	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	6.1	51
44	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
45	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	3.6	14
46	Alpha-fetoprotein-adjusted CHCC size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 209-219.	1.6	5
47	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	3.6	45
48	In Vivo ¹ H MRSpectroscopy of Biliary Components of Human Gallbladder at 7T. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 98-107.	1.9	3
49	Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors. <i>Gut</i> , 2021, 70, 1309-1317.	6.1	16
50	Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene". <i>Journal of Hepatology</i> , 2021, 74, 244-245.	1.8	0
51	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	1.8	96
52	Prevalence of anti-Hepatitis E antibodies and impact on disease severity in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 69-79.	1.8	4
53	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.4	0
54	Pathophysiological mechanisms of liver injury in COVID-19. <i>Liver International</i> , 2021, 41, 20-32.	1.9	273

#	ARTICLE	IF	CITATIONS
55	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	0.6	60
56	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	1.9	27
57	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 421-431.	1.0	4
58	Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 343-353.	1.4	89
59	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 335-344.	1.3	11
60	Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 441-451.	1.0	27
61	Primär biliäre Cholangitis (PBC). , 2021, , 368-376.		0
62	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. <i>Annals of Internal Medicine</i> , 2021, 174, 139-140.	2.0	6
63	COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center. <i>Pathology Research and Practice</i> , 2021, 217, 153305.	1.0	26
64	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , 2021, 9, 60.	1.4	37
65	Duration of obeticholic acid response in PBC patients who did not achieve poise trial criteria. , 2021, , .		0
66	Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2126.	1.8	3
67	From the origin of NASH to the future of metabolic fatty liver disease. <i>Gut</i> , 2021, 70, 1570-1579.	6.1	43
68	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. <i>FASEB Journal</i> , 2021, 35, e21217.	0.2	9
69	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. <i>Genes</i> , 2021, 12, 645.	1.0	41
70	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	1.1	5
71	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , 2021, 10, 48.	1.7	5
72	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	1.6	22

#	ARTICLE	IF	CITATIONS
73	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	1.9	12
74	Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases. <i>Journal of Autoimmunity</i> , 2021, 119, 102610.	3.0	7
75	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	2.0	16
76	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	3.6	101
77	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2021, 15, 922-933.	1.9	14
78	Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorus-31 Magnetic Resonance Spectroscopy Pilot Study. <i>Journal of Magnetic Resonance Imaging</i> , 2021, , .	1.9	2
79	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	1.9	36
80	Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2021, 41, 461-475.	1.8	28
81	24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation. <i>Journal of Hepatology</i> , 2021, 75, 1164-1176.	1.8	20
82	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , 2021, 41, 2249-2268.	1.9	64
83	The Addition of C-reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-3 Sodium Improves Prediction of Waitlist Mortality. <i>Hepatology</i> , 2021, 74, 1533-1545.	3.6	17
84	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , 2021, 41, 2622-2634.	1.9	3
85	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Hepatology Communications</i> , 2021, 5, 1939-1952.	2.0	8
86	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	1.1	16
87	New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. <i>United European Gastroenterology Journal</i> , 2021, 9, 947-954.	1.6	7
88	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. <i>Cells</i> , 2021, 10, 2516.	1.8	24
89	Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1243-1262.	1.9	50
90	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 634-646.	1.8	51

#	ARTICLE	IF	CITATIONS
91	Modern imaging of cholangitis. <i>British Journal of Radiology</i> , 2021, 94, 20210417.	1.0	7
92	On the Mechanisms of Biliary Flux. <i>Hepatology</i> , 2021, 74, 3497-3512.	3.6	10
93	Characterization of endogenous bile acid composition in individuals with cold-activated brown adipose tissue. <i>Molecular and Cellular Endocrinology</i> , 2021, 536, 111403.	1.6	4
94	Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 610-622.	0.7	11
95	Nuclear receptors in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166235.	1.8	23
96	Direct patient-physician communication via a hepatitis hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 452-460.	1.0	7
97	A life with bile acids: Alan F. Hofmann (1931-2021). <i>Journal of Hepatology</i> , 2021, 75, 1265-1266.	1.8	0
98	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1485-1493.	1.8	7
99	Proteomic Changes of Activated Hepatic Stellate Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12782.	1.8	8
100	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	1.1	10
101	The Tyrosine Kinase Tec Regulates Effector Th17 Differentiation, Pathogenicity, and Plasticity in T-Cell-Driven Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 750466.	2.2	5
102	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	2.4	57
103	Impact of adenoma detection rate on detection of advanced adenomas and endoscopic adverse events in a study of over 200,000 screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 135-141.	0.5	19
104	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	3.6	112
105	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 194-204.	1.9	45
106	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. <i>Hepatology</i> , 2020, 71, 1750-1765.	3.6	18
107	Optical control of the nuclear bile acid receptor FXR with a photohormone. <i>Chemical Science</i> , 2020, 11, 429-434.	3.7	22
108	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 1-11.	1.0	15

#	ARTICLE	IF	CITATIONS
109	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2712-2718.	1.1	4
110	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , 2020, 2, 100060.	2.6	9
111	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 533-542.	2.3	18
112	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	1.9	20
113	Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 369-377.	2.2	22
114	The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. <i>Hepatology</i> , 2020, 72, 584-594.	3.6	26
115	Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , 2020, 40, 894-904.	1.9	19
116	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020, 12, 2961.	1.7	8
117	PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8711.	1.8	13
118	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. <i>Annals of Internal Medicine</i> , 2020, 173, 350-361.	2.0	653
119	Pulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 467-468.	1.4	11
120	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020, 52, 1473-1479.	0.4	6
121	Soluble guanylyl cyclase stimulation and phosphodiesterase inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. <i>United European Gastroenterology Journal</i> , 2020, 8, 1174-1185.	1.6	20
122	EASL Recognition Award Recipient 2020: Prof. James L. Boyer. <i>Journal of Hepatology</i> , 2020, 73, 487-489.	1.8	0
123	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2020, 40, 2797-2807.	1.9	27
124	Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies. <i>Journal of Hepatology</i> , 2020, 73, S105.	1.8	4
125	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	1.9	12
126	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	1.9	14

#	ARTICLE	IF	CITATIONS
127	Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. <i>Journal of Hepatology</i> , 2020, 73, 651-663.	1.8	57
128	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ€—Z Variant of AAT (Piâ€—MZ vs) Tj ETQq0,0 0 rgBT/Overlock	0.6	63
129	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0233781.	1.1	32
130	Effective medical treatments for PSC needed ASAP - is AESOP the answer?. <i>Journal of Hepatology</i> , 2020, 73, 12-14.	1.8	1
131	Absence of Bsep/Abcb11 attenuates MCD dietâ€—induced hepatic steatosis but aggravates inflammation in mice. <i>Liver International</i> , 2020, 40, 1366-1377.	1.9	14
132	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00131.	1.3	68
133	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLARâ€—trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
134	Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?. <i>Nutrients</i> , 2020, 12, 765.	1.7	8
135	Lysosomal acid lipase is the major acid retinyl ester hydrolase in cultured human hepatic stellate cells but not essential for retinyl ester degradation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158730.	1.2	9
136	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. <i>Journal of Hepatology</i> , 2020, 72, 1122-1131.	1.8	47
137	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	1.9	21
138	Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. <i>Liver International</i> , 2020, 40, 1098-1110.	1.9	21
139	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , 2020, 40, 787-796.	1.9	14
140	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1619-1627.	1.4	12
141	Novel reliability criteria for controlled attenuation parameter assessments for nonâ€—invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	1.6	30
142	E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration. <i>Developmental Cell</i> , 2020, 52, 335-349.e7.	3.1	40
143	The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease. <i>Hepatology</i> , 2020, 72, 1117-1126.	3.6	29
144	Reply. <i>Hepatology</i> , 2020, 72, 1498-1499.	3.6	0

#	ARTICLE	IF	CITATIONS
145	NCOR1 Orchestrates Transcriptional Landscapes and Effector Functions of CD4+ T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 579.	2.2	13
146	Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 1620-1633.	1.9	20
147	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	51
148	Bile Acids and Bilirubin in Liver Immunology. , 2020, , 103-124.		0
149	S0984 Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, S501-S502.	0.2	0
150	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	6.1	100
151	Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. <i>Hepatology</i> , 2019, 69, 258-269.	3.6	83
152	The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. <i>European Radiology</i> , 2019, 29, 1048-1058.	2.3	18
153	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 127-135.	1.9	39
154	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 2374-2385.	1.9	47
155	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , 2019, 9, 11674.	1.6	6
156	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 781-793.	3.7	58
157	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	1.6	18
158	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019, 157, 705-719.e18.	0.6	82
159	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
160	PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells. <i>Hepatology Communications</i> , 2019, 3, 1191-1204.	2.0	26
161	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1113-1123.	1.6	55
162	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	1.1	10

#	ARTICLE	IF	CITATIONS
163	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 395-403.	1.0	13
164	Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model. <i>Laboratory Investigation</i> , 2019, 99, 1906-1917.	1.7	19
165	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019, 105, 102328.	3.0	86
166	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GSâ€9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 788-801.	3.6	180
167	Liver Injury and Failure in Critical Illness. <i>Hepatology</i> , 2019, 70, 2204-2215.	3.6	88
168	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	1.1	8
169	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. <i>Journal of Hepatology</i> , 2019, 71, 986-991.	1.8	44
170	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. <i>PLoS ONE</i> , 2019, 14, e0216677.	1.1	22
171	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4391-4404.	2.4	5
172	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	1.4	9
173	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	1.1	10
174	Management of patients with chronic hepatitis C failing repeated courses of interferonâ€free direct acting antiviral combination therapy. <i>GastroHep</i> , 2019, 1, 76-83.	0.3	5
175	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
176	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. <i>Journal of Lipid Research</i> , 2019, 60, 1284-1292.	2.0	27
177	THU-023-Monoacylglycerol lipase inhibition protects from hepatic inflammation and fibrosis in mouse models of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e170.	1.8	3
178	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 445-453.	3.7	116
179	High efficacy of interferonâ€free therapy for acute hepatitis C in HIVâ€positive patients. <i>United European Gastroenterology Journal</i> , 2019, 7, 507-516.	1.6	22
180	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.4	23

#	ARTICLE	IF	CITATIONS
181	Resection rates and safety profile of cold vs. hot snare polypectomy in polyps sized 5â€“10â€“mm and 11â€“20â€“mm. Digestive and Liver Disease, 2019, 51, 536-541.	0.4	15
182	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. United European Gastroenterology Journal, 2019, 7, 651-661.	1.6	7
183	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilsonâ€™s Disease. JHEP Reports, 2019, 1, 2-8.	2.6	13
184	Programmed cell death proteinâ€“1 (<sc>PD</sc>â€“1)â€“targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre realâ€“world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	1.9	106
185	Detection of Various Microplastics in Human Stool. Annals of Internal Medicine, 2019, 171, 453-457.	2.0	939
186	IDDF2019-ABS-0131â€“...Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
187	IDDF2019-ABS-0133â€“...Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0
188	Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. Immunity, 2019, 51, 1074-1087.e9.	6.6	72
189	Towards a nationwide implementation of a standardized nutrition and dietetics terminology in clinical practice: a pre-implementation focus group study including a pretest and using the consolidated framework for implementation research. BMC Health Services Research, 2019, 19, 920.	0.9	8
190	Fineâ€“tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. Hepatology, 2019, 69, 699-716.	3.6	33
191	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 203-217.	4.2	48
192	High seroprevalence of antiâ€“Hepatitis E antibodies in Austrian patients with autoimmune hepatitis. Liver International, 2019, 39, 640-645.	1.9	13
193	Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. Gastrointestinal Endoscopy, 2019, 89, 496-502.	0.5	25
194	Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut, 2019, 68, 522-532.	6.1	59
195	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatology Research, 2019, 49, 201-211.	1.8	16
196	Outcomes after placement of a SXâ€“ELLA oesophageal stent for refractory variceal bleedingâ€“A national multicentre study. Liver International, 2019, 39, 290-298.	1.9	30
197	Gut-liver axis signaling in portal hypertension. World Journal of Gastroenterology, 2019, 25, 5897-5917.	1.4	67
198	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Scientific Reports, 2018, 8, 6220.	1.6	155

#	ARTICLE	IF	CITATIONS
199	Na ⁺ /taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. <i>Hepatology</i> , 2018, 68, 1057-1069.	3.6	50
200	Colesevelam attenuates cholestatic liver and bile duct injury in <i>Mdr2</i> ^{+/+} mice by modulating composition, signalling and excretion of faecal bile acids. <i>Gut</i> , 2018, 67, 1683-1691.	6.1	53
201	[¹¹ C]acetate PET as a tool for diagnosis of liver steatosis. <i>Abdominal Radiology</i> , 2018, 43, 2963-2969.	1.0	3
202	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	1.9	31
203	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 321-350.	9.6	387
204	Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. <i>Annals of Intensive Care</i> , 2018, 8, 48.	2.2	24
205	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. <i>Journal of Hepatology</i> , 2018, 69, 368-377.	1.8	27
206	Chromosomal instability in HCC: a key function for checkpoint kinase 2. <i>Gut</i> , 2018, 67, 204-205.	6.1	2
207	Management of portal hypertension before and after liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 112-121.	1.3	19
208	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	1.9	28
209	Surveillance colonoscopy in Austria: Are we following the guidelines?. <i>Endoscopy</i> , 2018, 50, 119-127.	1.0	13
210	Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal—a Case Series. <i>Obesity Surgery</i> , 2018, 28, 812-819.	1.1	58
211	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. <i>Liver International</i> , 2018, 38, 523-531.	1.9	28
212	Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. <i>Liver International</i> , 2018, 38, 1188-1197.	1.9	8
213	Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. <i>Liver International</i> , 2018, 38, 1028-1035.	1.9	51
214	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 105-114.	1.0	14
215	Hepatocyte specific expression of an oncogenic variant of β -catenin results in lethal metabolic dysfunction in mice. <i>Oncotarget</i> , 2018, 9, 11243-11257.	0.8	6
216	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	0.7	11

#	ARTICLE	IF	CITATIONS
217	Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1049-1055.	1.6	16
218	Thyroid hormone receptor β 1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. <i>Journal of Lipid Research</i> , 2018, 59, 1610-1619.	2.0	14
219	A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. <i>Psychosomatic Medicine</i> , 2018, 80, 698-709.	1.3	75
220	Prevalence of <i>Helicobacter pylori</i> and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. <i>PLoS ONE</i> , 2018, 13, e0197695.	1.1	13
221	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018, 8, 9372.	1.6	39
222	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	5
223	NorUDCA promotes degradation of α 1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. <i>PLoS ONE</i> , 2018, 13, e0200897.	1.1	27
224	Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1777.	1.8	12
225	Waitlist mortality and post-transplant survival in patients with cholestatic liver disease – Impact of changes in allocation policy. <i>Hpb</i> , 2018, 20, 916-924.	0.1	14
226	miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. <i>Diabetes</i> , 2018, 67, 2541-2553.	0.3	60
227	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.4	7
228	Liver disease in adults with α 1-antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	1.6	23
229	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	1.1	20
230	Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes. <i>Cell Systems</i> , 2018, 6, 709-721.e6.	2.9	52
231	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.0	41
232	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 10054-10068.	0.8	25
233	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 184-190.	1.4	17
234	The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. <i>Hepatology</i> , 2017, 65, 1875-1890.	3.6	177

#	ARTICLE	IF	CITATIONS
235	Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?. <i>Hepatology</i> , 2017, 65, 1758-1761.	3.6	5
236	Renal replacement therapy in critically ill liver cirrhotic patientsâ€”outcome and clinical implications. <i>Liver International</i> , 2017, 37, 843-850.	1.9	55
237	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
238	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. <i>Journal of Hepatology</i> , 2017, 67, 110-119.	1.8	44
239	Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. <i>Digestive Diseases</i> , 2017, 35, 288-292.	0.8	31
240	Impact of higher-order heme degradation products on hepatic function and hemodynamics. <i>Journal of Hepatology</i> , 2017, 67, 272-281.	1.8	16
241	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1084-1103.	1.8	311
242	Circulating bile acids predict outcome in critically ill patients. <i>Annals of Intensive Care</i> , 2017, 7, 48.	2.2	49
243	Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. <i>United European Gastroenterology Journal</i> , 2017, 5, 104-110.	1.6	28
244	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
245	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-8.	0.6	13
246	Ultraâ€”highâ€”field magnetic resonance spectroscopy in nonâ€”alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in nonâ€”alcoholic steatohepatitis and advanced fibrosis. <i>Liver International</i> , 2017, 37, 1544-1553.	1.9	35
247	Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2017, 35, 282-287.	0.8	32
248	Use of inhibitors of the reninâ€”angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	1.6	49
249	Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis. <i>Clinical Liver Disease</i> , 2017, 9, 43-47.	1.0	6
250	Metabolic preconditioning protects BSEP/ABCB11âˆ™/âˆ™ mice against cholestatic liver injury. <i>Journal of Hepatology</i> , 2017, 66, 95-101.	1.8	51
251	Serum bile acids in patients with hepatopulmonary syndrome. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 361-367.	0.2	9
252	New therapeutic concepts in bile acid transport and signaling for management of cholestasis. <i>Hepatology</i> , 2017, 65, 1393-1404.	3.6	167

#	ARTICLE	IF	CITATIONS
253	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , 2017, 66, 724-733.	1.8	130
254	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.0	111
255	<scp>FXR</scp> controls <scp>CHOP</scp> expression in steatohepatitis. <i>FEBS Letters</i> , 2017, 591, 3360-3368.	1.3	15
256	Cystic Fibrosis-related Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 443-448.	0.9	80
257	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 309-316.	0.8	11
258	Molecular Mechanism of Taurocholate Transport by the Bile Salt Export Pump, an ABC Transporter Associated with Intrahepatic Cholestasis. <i>Molecular Pharmacology</i> , 2017, 92, 401-413.	1.0	12
259	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017, 49, 1360-1367.	0.4	28
260	AQP3 is regulated by PPAR β and JNK in hepatic stellate cells carrying PNPLA3 I148M. <i>Scientific Reports</i> , 2017, 7, 14661.	1.6	15
261	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance. <i>Investigative Radiology</i> , 2017, 52, 462-469.	3.5	14
262	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.0	9
263	Acid-base disorders in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1062-1073.	1.8	67
264	Adiponectin regulates AQP3 via PPAR α in human hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 51-54.	1.0	21
265	Vitamin D3 Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial. <i>Obesity Surgery</i> , 2017, 27, 1196-1207.	1.1	29
266	Hepatic gadoteric acid uptake as a measure of diffuse liver disease: Where are we?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 646-659.	1.9	54
267	Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. <i>Journal of Trace Elements in Medicine and Biology</i> , 2017, 39, 100-107.	1.5	28
268	Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. <i>Liver International</i> , 2017, 37, 224-231.	1.9	47
269	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. <i>Hepatology</i> , 2017, 65, 350-362.	3.6	444
270	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 8-15.	1.0	44

#	ARTICLE	IF	CITATIONS
271	The role of TIPS in the management of liver transplant candidates. United European Gastroenterology Journal, 2017, 5, 1100-1107.	1.6	23
272	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death and Disease, 2017, 8, e3135-e3135.	2.7	34
273	Single-sex infection with female Schistosoma mansoni cercariae mitigates hepatic fibrosis after secondary infection. PLoS Neglected Tropical Diseases, 2017, 11, e0005595.	1.3	20
274	PNPLA3 expression and its impact on the liver: current perspectives. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 55-66.	0.9	58
275	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Oncotarget, 2017, 8, 57109-57120.	0.8	5
276	The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0181878.	1.1	24
277	Ursodeoxycholic acid prevents ventricular conduction slowing and arrhythmia by restoring T-type calcium current in fetuses during cholestasis. PLoS ONE, 2017, 12, e0183167.	1.1	14
278	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget, 2017, 8, 46234-46248.	0.8	49
279	Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth, Clostridium difficile infection and polymyalgia rheumatica. BMJ Case Reports, 2016, 2016, bcr2015213465.	0.2	0
280	Recent advances in understanding and managing cholestasis. F1000Research, 2016, 5, 705.	0.8	46
281	Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice. BioMed Research International, 2016, 2016, 1-7.	0.9	11
282	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. Aids, 2016, 30, 1039-1047.	1.0	42
283	Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology, 2016, 64, 556-568.	3.6	148
284	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver International, 2016, 36, 1649-1656.	1.9	10
285	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transplant International, 2016, 29, 999-1007.	0.8	73
286	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology, 2016, 63, 1357-1367.	3.6	133
287	Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. Annals of Intensive Care, 2016, 6, 61.	2.2	28
288	Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. BMC Medicine, 2016, 14, 107.	2.3	20

#	ARTICLE	IF	CITATIONS
289	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. <i>Medicine (United States)</i> , 2016, 95, e4061.	0.4	18
290	Autophagy induced by exogenous bile acids is therapeutic in a model of Î±1-AT deficiency liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G156-G165.	1.6	27
291	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016, 65, 692-699.	1.8	245
292	Reply. <i>Hepatology</i> , 2016, 63, 346-347.	3.6	1
293	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	8.2	964
294	A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 924-929.	0.5	3
295	Indications for liver transplantation in adults. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 679-690.	1.0	39
296	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.	0.4	1
297	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. <i>EBioMedicine</i> , 2016, 11, 58-67.	2.7	45
298	Trends in quality of screening colonoscopy in Austria. <i>Endoscopy</i> , 2016, 48, 1102-1109.	1.0	31
299	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817
300	Liver Capsule: FXR agonists against liver disease. <i>Hepatology</i> , 2016, 64, 1773-1773.	3.6	15
301	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , 2016, 1, e000042.	2.0	194
302	Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. <i>British Journal of Cancer</i> , 2016, 115, 1421-1429.	2.9	29
303	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 414-420.	1.0	1
304	Endoscopic versus surgical management of biliary complications – Outcome analysis after 1188 orthotopic liver transplantations. <i>Digestive and Liver Disease</i> , 2016, 48, 1323-1329.	0.4	10
305	Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. <i>Journal of Hepatology</i> , 2016, 65, 856-858.	1.8	196
306	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [18F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 106-112.	1.6	5

#	ARTICLE	IF	CITATIONS
307	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2016, 64, 674-681.	1.8	143
308	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 2879-2885.	1.3	7
309	Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. <i>Digestive Diseases</i> , 2016, 34, 580-588.	0.8	41
310	Assessment of Orthotopic Liver Transplant Graft Survival on Gadoteric Acid-enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. <i>Investigative Radiology</i> , 2016, 51, 728-734.	3.5	34
311	The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. <i>Obesity Surgery</i> , 2016, 26, 2204-2212.	1.1	40
312	Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. <i>Obesity Surgery</i> , 2016, 26, 2425-2432.	1.1	48
313	Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2016, 36, 069-086.	1.8	80
314	Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect. <i>PLoS ONE</i> , 2016, 11, e0148210.	1.1	16
315	Hepatocyte specific expression of an oncogenic variant of β -catenin results in cholestatic liver disease. <i>Oncotarget</i> , 2016, 7, 86985-86998.	0.8	13
316	Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the <i>Abcb4</i> mouse model. <i>World Journal of Hepatology</i> , 2016, 8, 401.	0.8	40
317	Bile acids in regulation of inflammation and immunity: friend or foe?. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 25-31.	0.4	49
318	The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 328.	0.7	12
319	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1657-1665.	1.4	37
320	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015, 61, 85-90.	0.9	41
321	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. <i>Journal of Hepatology</i> , 2015, 62, 871-878.	1.8	55
322	Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoteric Acid-enhanced MR Imaging. <i>Radiology</i> , 2015, 277, 104-113.	3.6	95
323	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2340-2349.	0.7	23
324	Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. <i>Annals of Intensive Care</i> , 2015, 5, 47.	2.2	14

#	ARTICLE	IF	CITATIONS
325	Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow. <i>Digestive Diseases</i> , 2015, 33, 149-163.	0.8	31
326	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735.	1.9	10
327	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. <i>Journal of Hepatology</i> , 2015, 62, 1398-1404.	1.8	236
328	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
329	Multicenter analysis of soluble <i>Axl</i> reveals diagnostic value for very early stage hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 385-394.	2.3	41
330	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015, 35, 2121-2128.	1.9	72
331	Endoscopists with low adenoma detection rates benefit from high-definition endoscopy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 466-473.	1.3	21
332	Phosphatidylcholine contributes to in vivo ³¹ P MRS signal from the human liver. <i>European Radiology</i> , 2015, 25, 2059-2066.	2.3	19
333	Hepatic steatosis in Wilson disease – Role of copper and PNPLA3 mutations. <i>Journal of Hepatology</i> , 2015, 63, 156-163.	1.8	85
334	High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. <i>Endoscopy</i> , 2015, 47, 207-216.	1.0	25
335	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. <i>Digestive Diseases</i> , 2015, 33, 598-607.	0.8	33
336	Bile Acid-Induced Cholemic Nephropathy. <i>Digestive Diseases</i> , 2015, 33, 367-375.	0.8	48
337	Potential of Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. <i>Digestive Diseases</i> , 2015, 33, 433-439.	0.8	38
338	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. <i>Journal of Hepatology</i> , 2015, 62, S25-S37.	1.8	406
339	1,25-(OH) ₂ -vitamin D ₃ prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the <i>Abcb4</i> model. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 227-233.	1.0	37
340	Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. <i>Digestion</i> , 2015, 91, 286-293.	1.2	8
341	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 381-390.	1.9	111
342	A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection. <i>Endoscopy International Open</i> , 2015, 03, E19-E28.	0.9	8

#	ARTICLE	IF	CITATIONS
343	Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?. <i>Endoscopy</i> , 2015, 47, 898-902.	1.0	23
344	Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. <i>Molecular Endocrinology</i> , 2015, 29, 1320-1333.	3.7	10
345	A Greater Proportion of Liver Transplant Candidates Have Colorectal Neoplasia Than in the Healthy Screening Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 956-962.	2.4	15
346	Serum alkaline phosphatase levels accurately reflect cholestasis in mice. <i>Hepatology</i> , 2015, 62, 981-983.	3.6	20
347	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. <i>Archives of Toxicology</i> , 2015, 89, 2089-2103.	1.9	86
348	Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. <i>Hepatology</i> , 2015, 61, 613-626.	3.6	27
349	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015, 35, 876-885.	1.9	32
350	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143429.	1.1	23
351	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.	0.6	5
352	Comparative Analysis and Modeling of the Severity of Steatohepatitis in DDC-Treated Mouse Strains. <i>PLoS ONE</i> , 2014, 9, e111006.	1.1	11
353	Inflammatory Bowel Disease Alters Intestinal Bile Acid Transporter Expression. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1423-1431.	1.7	70
354	Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13529-13549.	1.8	46
355	Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies. <i>Digestive Diseases</i> , 2014, 32, 631-636.	0.8	18
356	Editorial for “Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis”. <i>Liver International</i> , 2014, 34, 328-329.	1.9	1
357	Epidemiological Trends of Hepatocellular Carcinoma in Austria. <i>Digestive Diseases</i> , 2014, 32, 664-669.	0.8	10
358	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. <i>Cell Metabolism</i> , 2014, 20, 787-798.	7.2	92
359	Incidence and mortality trends for biliary tract cancers in Austria. <i>Liver International</i> , 2014, 34, 1102-1108.	1.9	31
360	Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. <i>Hepatology</i> , 2014, 59, 858-869.	3.6	80

#	ARTICLE	IF	CITATIONS
361	Fibrate treatment for primary biliary cirrhosis. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 279-286.	1.0	36
362	Alterations of Canalicular ATP-Binding Cassette Transporter Expression in Drug-Induced Liver Injury. <i>Digestion</i> , 2014, 90, 81-88.	1.2	19
363	Bile acid receptors as targets for drug development. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 55-67.	8.2	565
364	Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. <i>Toxicology Letters</i> , 2014, 224, 186-195.	0.4	52
365	Nonselective β_2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	0.6	336
366	Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. <i>Journal of Hepatology</i> , 2014, 60, 1187-1193.	1.8	28
367	Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 854-860.	1.3	168
368	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014, 60, 118-126.	1.8	105
369	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014, 34, 69-77.	1.9	35
370	The Role of Canalicular ABC Transporters in Cholestasis. <i>Drug Metabolism and Disposition</i> , 2014, 42, 546-560.	1.7	65
371	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1287-1296.	1.8	139
372	Role of <i>FDFT1</i> polymorphism for fibrosis progression in patients with chronic hepatitis C. <i>Liver International</i> , 2014, 34, 388-395.	1.9	16
373	Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoteric Acid-enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. <i>Radiology</i> , 2014, 271, 739-747.	3.6	70
374	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. <i>Hepatology</i> , 2014, 59, 1972-1983.	3.6	105
375	Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 576-585.	3.1	71
376	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.	1.1	11
377	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1542-1552.	1.5	88
378	Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test. <i>Medical Oncology</i> , 2014, 31, 151.	1.2	14

#	ARTICLE	IF	CITATIONS
379	Application of localized ³¹ P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. <i>European Radiology</i> , 2014, 24, 1602-1609.	2.3	27
380	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , 2014, 16, 972-981.	4.6	198
381	Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 959-970.	1.8	66
382	Clinical application of transcriptional activators of bile salt transporters. <i>Molecular Aspects of Medicine</i> , 2014, 37, 57-76.	2.7	50
383	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303.	1.8	129
384	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 544-549.	1.8	43
385	Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. <i>Toxicology Letters</i> , 2014, 228, 56-66.	0.4	81
386	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , 2014, 60, 1135-1142.	1.8	39
387	Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 683-689.	2.4	146
388	Pharmacological correction of misfolding of ABC proteins. <i>Drug Discovery Today: Technologies</i> , 2014, 12, e87-e94.	4.0	14
389	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	1.1	55
390	Primary Sclerosing Cholangitis (PSC)., 2014, , 301-316.		0
391	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013, 33, 561-568.	1.9	16
392	Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. <i>Journal of Hepatology</i> , 2013, 58, 1201-1208.	1.8	84
393	Bile acids induce arrhythmias in human atrial myocardium implications for altered serum bile acid composition in patients with atrial fibrillation. <i>Heart</i> , 2013, 99, 1685-1692.	1.2	73
394	Animal Models of Cholestasis. , 2013, , 331-349.		3
395	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2261-2273.	3.6	288
396	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: Possible implications for sclerosing cholangitis. <i>Journal of Hepatology</i> , 2013, 58, 750-756.	1.8	24

#	ARTICLE	IF	CITATIONS
397	Bile acid transporters and regulatory nuclear receptors in the liver and beyond. <i>Journal of Hepatology</i> , 2013, 58, 155-168.	1.8	304
398	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 911-921.	1.8	269
399	The PPAR α agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 1555-1565.	1.2	32
400	Bile Acids as Modulators of Gut Microbiota Linking Dietary Habits and Inflammatory Bowel Disease: A Potentially Dangerous Liaison. <i>Gastroenterology</i> , 2013, 144, 844-846.	0.6	13
401	Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats. <i>Liver International</i> , 2013, 33, 283-293.	1.9	19
402	Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2013, 17, 161-189.	1.0	87
403	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 200-219.	1.0	43
404	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
405	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2224-2234.	3.6	101
406	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF α expression in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2013, 1, 265-275.	1.6	26
407	Bile Acid-Mediated Control of Liver Triglycerides. <i>Seminars in Liver Disease</i> , 2013, 33, 330-342.	1.8	55
408	The liver in sepsis. <i>Current Opinion in Critical Care</i> , 2013, 19, 123-127.	1.6	73
409	Hypoxic liver injury and cholestasis in critically ill patients. <i>Current Opinion in Critical Care</i> , 2013, 19, 128-132.	1.6	75
410	Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. <i>Hepatology</i> , 2013, 58, 2056-2069.	3.6	130
411	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013, 62, 1634-1641.	6.1	275
412	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	1.0	15
413	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: New light on an old paradox. <i>Hepatology</i> , 2013, 57, 2106-2109.	3.6	10
414	Low vitamin D levels are associated with impaired virologic response to PEGIFN α 2a+ α 2b therapy in HIV α 1 hepatitis C virus coinfecting patients. <i>Aids</i> , 2013, 27, 227-232.	1.0	39

#	ARTICLE	IF	CITATIONS
415	A4.6â€¦Effects of Cholic Acid and its Derivatives in Experimental Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A25.2-A26.	0.5	0
416	Sulphatation Does Not Appear to Be a Protective Mechanism to Prevent Oxysterol Accumulation in Humans and Mice. <i>PLoS ONE</i> , 2013, 8, e68031.	1.1	5
417	Evolving concepts in primary sclerosing cholangitis. <i>Liver International</i> , 2012, 32, 352-369.	1.9	25
418	Liver Dysfunction and Phosphatidylinositol-3-Kinase Signalling in Early Sepsis: Experimental Studies in Rodent Models of Peritonitis. <i>PLoS Medicine</i> , 2012, 9, e1001338.	3.9	152
419	Animal models of biliary tract injury. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 239-243.	1.0	9
420	A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIVâ€“HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1327-1334.	0.6	27
421	Liver Transplantation. <i>Investigative Radiology</i> , 2012, 47, 353-358.	3.5	34
422	Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. <i>Laboratory Investigation</i> , 2012, 92, 857-867.	1.7	38
423	Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis. <i>Gastroenterology</i> , 2012, 142, 355-365.e4.	0.6	243
424	Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. <i>Journal of Human Genetics</i> , 2012, 57, 564-567.	1.1	21
425	Common genetic variation in vitamin D metabolism is associated with liver stiffness. <i>Hepatology</i> , 2012, 56, 1883-1891.	3.6	54
426	Sedation in Screening Colonoscopy: Impact on Quality Indicators And Complications. <i>American Journal of Gastroenterology</i> , 2012, 107, 1837-1848.	0.2	77
427	Association of 25â€“hydroxyvitamin <scp>D</scp> levels with liver dysfunction and mortality in chronic liver disease. <i>Liver International</i> , 2012, 32, 845-851.	1.9	97
428	The interaction of hepatic lipid and glucose metabolism in liver diseases. <i>Journal of Hepatology</i> , 2012, 56, 952-964.	1.8	728
429	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 492-498.	1.8	48
430	Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , 2012, 56, 1439-1447.	3.6	158
431	Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. <i>Hepatology</i> , 2012, 56, 2297-2304.	3.6	68
432	An In Silico Classification Model for Putative ABCC2 Substrates. <i>Molecular Informatics</i> , 2012, 31, 547-553.	1.4	18

#	ARTICLE	IF	CITATIONS
433	Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury. <i>Gastroenterology</i> , 2012, 142, 140-151.e12.	0.6	139
434	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 585-592.	1.2	74
435	Primary Sclerosing Cholangitis: New Approaches to Diagnosis, Surveillance and Treatment. <i>Digestive Diseases</i> , 2012, 30, 39-47.	0.8	26
436	Xenobiotic-induced liver injury and fibrosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 571-580.	1.5	17
437	Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans. <i>Digestion</i> , 2012, 86, 244-249.	1.2	6
438	Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. <i>Hepatology</i> , 2012, 56, 270-280.	3.6	75
439	Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. <i>International Journal of Cancer</i> , 2012, 130, 2232-2239.	2.3	80
440	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 395-402.	1.0	93
441	Hepatobiliary transporter expression and postoperative jaundice in patients undergoing partial hepatectomy. <i>Liver International</i> , 2012, 32, 119-127.	1.9	6
442	Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis. <i>PLoS ONE</i> , 2012, 7, e46584.	1.1	97
443	Loss of CFTR Affects Biliary Epithelium Innate Immunity and Causes TLR4- $\text{NF-}\kappa\text{B}$ -Mediated Inflammatory Response in Mice. <i>Gastroenterology</i> , 2011, 141, 1498-1508.e5.	0.6	114
444	Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 602-608.e1.	2.4	57
445	Nuclear Receptors as New Perspective for the Management of Liver Diseases. <i>Gastroenterology</i> , 2011, 140, 1120-1125.e12.	0.6	94
446	Will we ever model PSC? — It's hard to be a PSC model! <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 792-804.	0.7	56
447	ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- α and PGC-1. <i>Nature Medicine</i> , 2011, 17, 1076-1085.	15.2	612
448	Pathogenesis of primary sclerosing cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 727-739.	1.0	104
449	Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 867-878.	1.8	75
450	Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. <i>Journal of Hepatology</i> , 2011, 55, 876-884.	1.8	32

#	ARTICLE	IF	CITATIONS
451	Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia. <i>Science</i> , 2011, 333, 233-238.	6.0	475
452	Mycosis as a Cause of Secondary Sclerosing Cholangitis Requiring Liver Retransplantation. <i>Transplantation</i> , 2011, 91, e14-e16.	0.5	2
453	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. <i>Virchows Archiv Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 511-523.	1.4	116
454	Fibrosis in Autoimmune and Cholestatic Liver Disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 245-258.	1.0	65
455	Nuclear receptors in liver disease. <i>Hepatology</i> , 2011, 53, 1023-1034.	3.6	226
456	Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the <i>Mdr2</i> ^{-/-} (<i>Abcb4</i> ^{-/-}) mouse cholangiopathy model by promoting biliary HCO ₃ ⁻ output. <i>Hepatology</i> , 2011, 54, 1303-1312.	3.6	193
457	Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. <i>Gut</i> , 2011, 60, 387-396.	6.1	38
458	Sex-Specific Prevalence of Adenomas, Advanced Adenomas, and Colorectal Cancer in Individuals Undergoing Screening Colonoscopy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1352.	3.8	225
459	Targeting Nuclear Bile Acid Receptors for Liver Disease. <i>Digestive Diseases</i> , 2011, 29, 98-102.	0.8	24
460	Ursodeoxycholic Acid for Treatment of Fatty Liver Disease and Dyslipidemia in Morbidly Obese Patients. <i>Digestive Diseases</i> , 2011, 29, 117-118.	0.8	8
461	Farnesoid X receptor represses hepatic human APOA gene expression. <i>Journal of Clinical Investigation</i> , 2011, 121, 3724-3734.	3.9	92
462	Hepatobiliäre Funktionsstörungen und Leberversagen. , 2011, , 567-578.		0
463	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. , 2010, 126, 228-243.		79
464	Disruption of the growth hormone-Signal transducer and activator of transcription 5-Insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. <i>Hepatology</i> , 2010, 51, 1319-1326.	3.6	48
465	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauro lithocholic acid-induced cholestasis in rat liver. <i>Hepatology</i> , 2010, 52, 1758-1768.	3.6	36
466	The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. <i>Laboratory Investigation</i> , 2010, 90, 844-852.	1.7	38
467	Curcumin improves sclerosing cholangitis in <i>Mdr2</i> ^{-/-} mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. <i>Gut</i> , 2010, 59, 521-530.	6.1	83
468	Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development. <i>Toxicological Sciences</i> , 2010, 118, 485-500.	1.4	302

#	ARTICLE	IF	CITATIONS
469	The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C23-ester Glucuronide in the Liver. <i>Journal of Biological Chemistry</i> , 2010, 285, 1113-1121.	1.6	19
470	New Insights into Autoimmune Cholangitis through Animal Models. <i>Digestive Diseases</i> , 2010, 28, 99-104.	0.8	28
471	Nuclear Receptor Regulation of the Adaptive Response of Bile Acid Transporters in Cholestasis. <i>Seminars in Liver Disease</i> , 2010, 30, 160-177.	1.8	90
472	Signal Transducer and Activator of Transcription 3 Protects From Liver Injury and Fibrosis in a Mouse Model of Sclerosing Cholangitis. <i>Gastroenterology</i> , 2010, 138, 2499-2508.	0.6	71
473	Fatty liver and lipotoxicity. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 299-310.	1.2	232
474	Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. <i>Atherosclerosis</i> , 2010, 209, 178-183.	0.4	50
475	Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism. <i>Digestive Diseases</i> , 2010, 28, 220-224.	0.8	254
476	Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiographyâ€”The Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , 2010, 208, 564-571.	0.4	42
477	Bile Acids and Their Receptors. , 2010, , 317-332.		0
478	Synthetic LXR agonist attenuates plaque formation in apoE ^{-/-} mice without inducing liver steatosis and hypertriglyceridemia. <i>Journal of Lipid Research</i> , 2009, 50, 312-326.	2.0	121
479	Hepatocyte nuclear factor-4 β and bile acids regulate human concentrative nucleoside transporter-1 gene expression. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G936-G947.	1.6	13
480	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 ^{-/-} mice. <i>Hepatology</i> , 2009, 49, 1972-1981.	3.6	135
481	The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. <i>Hepatology</i> , 2009, 50, 893-899.	3.6	10
482	Imbalance of proâ€•and antifibrogenic genes and bile duct injury in murine <i>Schistosoma mansoni</i> infectionâ€•induced liver fibrosis. <i>Tropical Medicine and International Health</i> , 2009, 14, 1418-1425.	1.0	13
483	Nuclear receptors as therapeutic targets in cholestatic liver diseases. <i>British Journal of Pharmacology</i> , 2009, 156, 7-27.	2.7	143
484	Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. <i>Liver International</i> , 2009, 29, 1316-1325.	1.9	31
485	Evaluation of indocyanine green clearance and model for endâ€•stage liver disease for estimation of shortâ€•term prognosis in decompensated cirrhosis. <i>Liver International</i> , 2009, 29, 1516-1520.	1.9	33
486	When lightning strikes twice: The plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2009, 50, 633-635.	1.8	13

#	ARTICLE	IF	CITATIONS
487	New molecular insights into the mechanisms of cholestasis. <i>Journal of Hepatology</i> , 2009, 51, 565-580.	1.8	241
488	Nuclear receptor ligands in therapy of cholestatic liver disease. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 4299.	3.0	10
489	Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts. <i>American Journal of Pathology</i> , 2009, 175, 2392-2405.	1.9	154
490	Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. <i>Wiener Medizinische Wochenschrift</i> , 2008, 158, 542-548.	0.5	102
491	Nuclear bile acid receptor farnesoid X receptor meets nuclear factor- κ B: New insights into hepatic inflammation. <i>Hepatology</i> , 2008, 48, 1383-1386.	3.6	37
492	Role of hepatic phospholipids in development of liver injury in <i>Mdr2</i> (<i>Abcb4</i>) knockout mice. <i>Liver International</i> , 2008, 28, 948-958.	1.9	23
493	Validated Comprehensive Analytical Method for Quantification of Coenzyme A Activated Compounds in Biological Tissues by Online Solid-Phase Extraction LC/MS/MS. <i>Analytical Chemistry</i> , 2008, 80, 5736-5742.	3.2	51
494	Mechanisms of Cholestasis. <i>Clinics in Liver Disease</i> , 2008, 12, 1-26.	1.0	166
495	Ischemia and Cholestasis: More Than (Just) the Bile Ducts!. <i>Transplantation</i> , 2008, 85, 1083-1085.	0.5	12
496	Fatal hemobilia resulting from an iatrogenic arteriobiliary fistula as a rare complication of transjugular liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 83-86.	0.8	17
497	MDR3 (ABCB4) Defects: A Paradigm for the Genetics of Adult Cholestatic Syndromes. <i>Seminars in Liver Disease</i> , 2007, 27, 077-098.	1.8	188
498	Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1694-1699.	1.7	12
499	The Importance of Serum Bile Acid Level Analysis and Treatment With Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy. <i>Archives of Dermatology</i> , 2007, 143, 757-62.	1.7	45
500	Removal of Bile Acids by Two Different Extracorporeal Liver Support Systems in Acute-on-Chronic Liver Failure. <i>ASAIO Journal</i> , 2007, 53, 187-193.	0.9	50
501	A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis. <i>American Journal of Pathology</i> , 2007, 171, 525-536.	1.9	293
502	Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. <i>Molecular Pharmaceutics</i> , 2007, 4, 895-910.	2.3	22
503	Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA. <i>Gastroenterology</i> , 2007, 132, 330-342.	0.6	725
504	Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. <i>Hepatology</i> , 2007, 46, 776-784.	3.6	77

#	ARTICLE	IF	CITATIONS
505	A little orphan runs to fat: The orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. <i>Hepatology</i> , 2007, 46, 1-5.	3.6	53
506	Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2007, 27, 920-929.	1.9	103
507	Extrahepatic cholestasis downregulates Oatp1 by TNF- α signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver. <i>Liver International</i> , 2007, 27, 1056-1065.	1.9	23
508	Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 283-308.	1.9	275
509	Lithocholic Acid Feeding Induces Segmental Bile Duct Obstruction and Destructive Cholangitis in Mice. <i>American Journal of Pathology</i> , 2006, 168, 410-422.	1.9	161
510	24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice. <i>Gastroenterology</i> , 2006, 130, 465-481.	0.6	282
511	Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations. <i>Molecular Pharmaceutics</i> , 2006, 3, 231-251.	2.3	288
512	Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 574-585.	1.7	193
513	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. <i>Journal of Hepatology</i> , 2006, 44, 243-245.	1.8	32
514	Clinical-Pathological Conference Series from the Medical University of Graz. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 769-775.	1.0	3
515	Molecular mechanisms of cholestasis. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 380-385.	0.5	57
516	Bilirubin Kinetic Modeling for Quantification of Extracorporeal Liver Support. <i>Blood Purification</i> , 2006, 24, 413-422.	0.9	11
517	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST α -OST β in cholestasis in humans and rodents. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G1124-G1130.	1.6	255
518	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-1 α /1 β in the adaptive response to bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G923-G932.	1.6	154
519	Fxr $^{-/-}$ mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. <i>Journal of Lipid Research</i> , 2006, 47, 582-592.	2.0	98
520	Hepatobiliary transporter expression in human hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 367-379.	1.9	112
521	Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. <i>Hepatology</i> , 2005, 41, 470-477.	3.6	40
522	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. <i>Hepatology</i> , 2005, 42, 420-430.	3.6	295

#	ARTICLE	IF	CITATIONS
523	Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis. <i>Annals of Hepatology</i> , 2005, 4, 77-99.	0.6	42
524	Hepatotoxicity of NONI juice: Report of two cases. <i>World Journal of Gastroenterology</i> , 2005, 11, 4758.	1.4	118
525	Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G831-G841.	1.6	94
526	Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G798-G805.	1.6	67
527	Pathophysiological Role of Poly(ADP-Ribose) Polymerase (PARP) Activation during Acetaminophen-Induced Liver Cell Necrosis in Mice. <i>Toxicological Sciences</i> , 2005, 84, 201-208.	1.4	32
528	Molecular Regulation of Hepatobiliary Transport Systems. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S111-S124.	1.1	148
529	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , 2005, 129, 476-485.	0.6	268
530	Oncosis represents the main type of cell death in mouse models of cholestasis. <i>Journal of Hepatology</i> , 2005, 42, 378-385.	1.8	80
531	In vivo quantification of liver dialysis: Comparison of albumin dialysis and fractionated plasma separation. <i>Journal of Hepatology</i> , 2005, 43, 451-457.	1.8	146
532	Mdr2 (Abcb4) ^{-/-} mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. <i>Journal of Hepatology</i> , 2005, 43, 1045-1054.	1.8	228
533	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , 2005, 129, 476-485.	0.6	235
534	The keratin cytoskeleton in liver diseases. <i>Journal of Pathology</i> , 2004, 204, 367-376.	2.1	121
535	Spontaneous cholecysto- and hepatolithiasis in Mdr2 ^{+/?} mice: A model for low phospholipid-associated cholelithiasis. <i>Hepatology</i> , 2004, 39, 117-128.	3.6	148
536	The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope?. <i>Hepatology</i> , 2004, 40, 260-263.	3.6	19
537	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. <i>Gastroenterology</i> , 2004, 127, 261-274.	0.6	525
538	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 220-230.	1.0	30
539	Acquired Alterations of Transporter Expression and Function in Cholestasis. , 2004, , 266-288.		1
540	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. <i>Gastroenterology</i> , 2003, 125, 825-838.	0.6	252

#	ARTICLE	IF	CITATIONS
541	When bile ducts say NO: The good, the bad, and the ugly. <i>Gastroenterology</i> , 2003, 124, 847-851.	0.6	17
542	Molecular aspects of bile formation and cholestasis. <i>Trends in Molecular Medicine</i> , 2003, 9, 558-564.	3.5	94
543	Down-regulation of the Na ⁺ /taurocholate cotransporting polypeptide during pregnancy in the rat. <i>Journal of Hepatology</i> , 2003, 38, 148-155.	1.8	39
544	Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. <i>Journal of Hepatology</i> , 2003, 38, 387-394.	1.8	46
545	Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2003, 38, 419-425.	1.8	221
546	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 717-727.	1.8	260
547	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. <i>Journal of Hepatology</i> , 2003, 39, 480-488.	1.8	171
548	Successful conservative management of acute hepatic failure following exertional heatstroke. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1135-1139.	0.8	21
549	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2003, 19, 216-231.	1.0	13
550	Bile Salt Transporters: Molecular Characterization, Function, and Regulation. <i>Physiological Reviews</i> , 2003, 83, 633-671.	13.1	873
551	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 314-329.	1.0	6
552	Bile Acid-Induced Mallory Body Formation in Drug-Primed Mouse Liver. <i>American Journal of Pathology</i> , 2002, 161, 2019-2026.	1.9	43
553	Cytokeratins as Targets for Bile Acid-Induced Toxicity. <i>American Journal of Pathology</i> , 2002, 160, 491-499.	1.9	40
554	Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangiocytes. <i>Gastroenterology</i> , 2002, 123, 1238-1251.	0.6	287
555	Alterations of hepatobiliary transporter expression in primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , 2002, 36, 28-29.	1.8	2
556	Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G184-G191.	1.6	66
557	Hepatic transport systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S105-S112.	1.4	25
558	Abnormal hepatic sinusoidal bile acid transport: New insights into the pathogenesis of cholestasis?. <i>Gastroenterology</i> , 2001, 120, 321-322.	0.6	1

#	ARTICLE	IF	CITATIONS
559	Effects of Ursodeoxycholic and Cholic Acid Feeding on Hepatocellular Transporter Expression in Mouse Liver. <i>Gastroenterology</i> , 2001, 121, 170-183.	0.6	254
560	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 242-256.	1.0	13
561	Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. <i>Hepatology</i> , 2001, 33, 633-646.	3.6	324
562	No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. <i>American Journal of Gastroenterology</i> , 2001, 96, 2286-2287.	0.2	36
563	Intra-hepatic haematoma complicating transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome associated with anti-phospholipid antibodies, aplastic anaemia and chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 813-816.	0.8	21
564	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2000, 16, 239-250.	1.0	0
565	Hepatocellular Bile Salt Transport: Lessons from Cholestasis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 99D-104D.	1.8	6
566	Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. <i>Gastroenterology</i> , 2000, 118, 163-172.	0.6	240
567	Inflammation-induced cholestasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 946-959.	1.4	206
568	Molecular regulation of hepatocellular transport systems in cholestasis. <i>Journal of Hepatology</i> , 1999, 31, 165-178.	1.8	148
569	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 1999, 15, 217-228.	1.0	3
570	Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. <i>Hepatology</i> , 1998, 28, 646-654.	3.6	17
571	Maternal cholestasis does not affect the ontogenic pattern of expression of the Na ⁺ /Taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. <i>Hepatology</i> , 1998, 28, 789-795.	3.6	22
572	Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. <i>Hepatology</i> , 1998, 28, 1081-1087.	3.6	68
573	Nitric oxide and guanosine 3',5'-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. <i>Hepatology</i> , 1998, 28, 1621-1628.	3.6	27
574	Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. <i>Journal of Hepatology</i> , 1998, 28, 812-819.	1.8	25
575	Molecular Pathogenesis of Cholestasis. <i>New England Journal of Medicine</i> , 1998, 339, 1217-1227.	13.9	719
576	Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. <i>American Journal of Gastroenterology</i> , 1998, 93, 1985-1986.	0.2	7

#	ARTICLE	IF	CITATIONS
577	Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. <i>Journal of Hepatology</i> , 1997, 27, 163-169.	1.8	72
578	Endoscopic intracorporeal laser lithotripsy of difficult common bile duct stones with a stone-recognition pulsed dye laser system. <i>Gastrointestinal Endoscopy</i> , 1995, 42, 416-419.	0.5	48
579	Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by other Nuclear Receptors. , 0, , 275-300.		0